Alector to Present at the BTIG Virtual Biotechnology Conference 2020

On August 4, 2020 Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, reported that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020, at 11:00 a.m. ET (Press release, Alector, AUG 4, 2020, View Source [SID1234562821]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the "Events & Presentations" page within the Investors section of the Alector website at View Source A replay will be available on the Alector website for 30 days following the event.

Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4

On August 4, 2020 Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a clinical-stage cancer immunotherapy company, reported it has been awarded a Small Business Innovation Research (SBIR) Direct to Phase II grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) (Press release, Immune-Onc Therapeutics, AUG 4, 2020, View Source [SID1234562841]). The grant, in the amount of $2.14 million over two years, will support development of IO-202, a first-in-class antibody targeting leukocyte immunoglobulin-like receptor B4 (LILRB4), for acute myeloid leukemia (AML), the most common acute leukemia in adults, and for chronic myelomonocytic leukemia (CMML), a rare form of leukemia. The highly competitive SBIR programs enable small businesses to explore technological potential and pursue commercialization of innovations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to receive financial support and scientific endorsement from the National Cancer Institute," said Charlene Liao, Ph.D., chief executive officer of Immune-Onc. "This Direct to Phase II SBIR award will help us advance our lead clinical program. We look forward to working with our investigators to initiate the first-in-human trial of IO-202 in two forms of leukemia: AML and CMML. We also plan to evaluate IO-202 in other blood cancers and solid tumors in the future."

In May, Immune-Onc’s IO-202 Investigational New Drug (IND) application received clearance from the U.S. Food and Drug Administration (FDA). In preclinical studies, IO-202 has shown evidence of activating T cell cytotoxicity against leukemia cells and blocking tumor infiltration. Immune-Onc’s first Phase I trial with IO-202 will evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in AML patients with monocytic differentiation and in CMML patients.

ABOUT AML and CMML

AML, the most common acute leukemia (blood and bone marrow cancer) in adults, is characterized by the proliferation of abnormal myeloblasts (a type of white blood cell) in the bone marrow. Nearly 20,000 new cases are expected in the U.S. in 2020. Despite advances in treatment, less than 30 percent of acute myeloid leukemia patients are alive five years after initial diagnosis.

CMML is a cancer that starts in blood-forming cells in the bone marrow and invades the blood. The condition is rare, with about 1,100 cases in the U.S. each year.

ABOUT IO-202

IO-202 is a first-in-class monoclonal antibody that blocks signaling of leukocyte immunoglobulin-like receptor B4 (LILRB4), an immune inhibitory receptor, with high binding affinity and specificity. In October 2018, Immune-Onc and The University of Texas announced the publication of pioneering research in Nature (DOI: 10.1038/s41586-018-0615-z) illuminating the roles of LILRB4 in immune suppression and tumor infiltration in AML. IO-202 is the first T-cell activator for AML. Preclinical studies showed that IO-202 can convert a "don’t kill me" to "kill me" signal by activating T cell killing of AML cells and a "don’t find me" to "find me" signal by inhibiting leukemia infiltration. IO-202 will be evaluated in AML and CMML in a Phase I trial, and Immune-Onc plans to explore its potential in other hematologic malignancies and solid tumors in future trials.

Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer Surgery

On August 4, 2020 Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, reported positive top-line data demonstrating that the company’s recently completed Phase 2/3 registration study of the use of pegloprastide (AVB-620) during surgery met its primary endpoint of detecting cancer in margin specimens in real time (p<0.001) (Press release, Avelas Biosciences, AUG 4, 2020, View Source [SID1234562749]). Pegloprastide is designed to deliver a fluorescent marker specifically to cancer cells for surgeons to identify cancerous tissue in real-time to reduce repeat surgeries and improve patient outcomes. The pivotal study evaluated the safety and efficacy of pegloprastide in women with primary, nonrecurrent breast cancer undergoing surgery. In more than 150 patients dosed to date, no drug-related serious adverse events were reported.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With pegloprastide, we are removing the blindfold and helping surgeons see where the cancer is to make informed, real-time decisions in the operating room," said Jay Lichter, Ph.D., Chairman, President, and Chief Executive Officer of Avelas. "This pivotal clinical data is a first in the field of fluorescence image-guided surgery for breast cancer and supports the use of pegloprastide to revolutionize surgical treatment with the goal of eliminating tens of thousands of repeat surgeries undertaken to address positive margins."

The presence of positive margins is a significant challenge in breast-conserving surgery. Positive surgical margins occur when post-operative pathology indicates cancer cells are present at the edge of removed tissue, indicating that not all the malignant tissue was removed during an operation. It is estimated that each year in the United States more than 260,000 women undergo a lumpectomy, of which one-third (more than 80,000) are repeat surgeries with the goal of achieving negative margins.1 Beyond that, of the estimated 90,000 women who choose a mastectomy, many choose it for fear of incomplete initial lumpectomy.1

"Cancer recurrence and metastasis is more likely with positive margins, and the significant re-excision rate with standard of care for lumpectomies to try to obtain negative margins is driving women to get second lumpectomies, causing significant pain and physical limitations," said Sheldon M. Feldman, M.D., chief, division of breast surgery and surgical oncology, and director, Breast Cancer Services at Montefiore Einstein Center for Cancer Care and professor of surgery, Albert Einstein College of Medicine. "Pegloprastide has the potential to greatly improve a breast surgeon’s ability to achieve negative margins and reduce the number of re-excisions, potentially improving outcomes for hundreds of thousands of women and saving thousands of lives."

Top-line data showed the planned re-excision rate for patients who underwent breast cancer surgery with pegloprastide was 6%, much lower than the typical re-excision rate of 20-40%.2-7 For the study, surgeons first excised the tumor using standard of care methods followed by interoperative imaging of both the excised tissue and the surgical site using pegloprastide and a specialized fluorescent imaging device manufactured for Avelas by Quest Medical Imaging, based on its QUEST SPECTRUM platformtechnology. With pegloprastide, 75% of the patients, who still had positive margins, were able to be identified.

Steven Chen, M.D., Chief Medical Officer of Avelas Biosciences, said, "Today, in an era of patient-centered care, high re-excision rates need to become a historical artifact. This data indicates that pegloprastide could significantly reduce the need for these repeat breast cancer surgeries driven by positive margins. We are grateful to our clinical collaborators and especially to the patients who participated in this pivotal trial as we advance pegloprastide to meaningfully improve surgical outcomes for breast cancer and beyond."

The primary endpoint of Period 2 of the pivotal study was the ability to detect cancer in margin-relevant tissue, using pegloprastide fluorescence imaging, in sufficient number of patients to demonstrate efficacy; this was achieved with high statistical significance (p-value < 0.001). The secondary endpoint of intraoperative patient-level cancer detection performance in margin-relevant tissue, using prespecified thresholds, indicated that up to 75% of patients that would have had a positive margin could benefit from this investigation product at a statistically significant level. During the trial, patients were administered pegloprastide either the day before surgery or the day of surgery; initial data supports pegloprastide administration the day before the surgery as the preferred dosing time. Other secondary and exploratory endpoints included false positives, specimen and sample type detection, and planned re-excisions. All showed strong indications supporting efficacy and utility of pegloprastide. The study showed no serious adverse events or laboratory abnormalities attributable to the infusion of pegloprastide.

About the Phase 2/3 Trial

The pivotal Phase 2/3 study of pegloprastide was a multi-center, open-label, single-arm study designed to evaluate patients during two separate trial periods. Period 1, which was completed in December 2017, enrolled 32 patients and demonstrated proof-of-concept that pegloprastide could sensitively visualize the primary tumor in the lumpectomy specimen. In addition, optimal dosing and imaging conditions, including fluorescent thresholds, to achieve differentiation between malignant and nonmalignant tissue in margin-relevant tissue was determined. Period 2, which is expected to be a registration study, was completed in March 2020 and enrolled 92 additional patients to prospectively assess the ability of pegloprastide to identify malignant tissue at or close to the surface of excised tissue and of tissue that would otherwise have been left behind and require a reoperation to remove. Both study periods enrolled women with the most common breast cancer types – DCIS (Stage 0) and/or Stage I-III invasive carcinoma – with all grades (Grades 1-3) and all receptor statuses. Imaging of pegloprastide was performed on all types of tissue, including excised specimen, cavity shaves, and residual tissue left in the surgical cavity.For more information, visit www.clinicaltrials.gov.

About Pegloprastide (AVB-620) and QUEST SPECTRUM Fluorescent Imaging Device

Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is the only fluorescence-based clinical cancer detection product that uses the ratio of two fluorophores within the same molecule (ratiometric imaging) to provide more accurate and actionable information. Pegloprastide’s ratiometric readout attenuates common artifacts of fluorescent imaging, including differences in drug concentration and distance of the camera from the tissue area of interest. QUEST SPECTRUM device has a wide field of view (~10 cm) and provides a rapid assessment of tissue (~100 ms). Beyond breast cancer, Avelas has plans to explore the use of pegloprastide during surgery for other types of cancer, including ovarian, colorectal, head and neck, melanoma, and sarcoma.

Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the Best Innovations in Cancer Care Beyond Medicine

On August 4, 2020 Astellas Pharma US, Inc. ("Astellas") reported the call for entries for the Astellas Oncology C3 Prize (Changing Cancer Care), a global challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones (Press release, Astellas, AUG 4, 2020, View Source [SID1234562765]). Now in its fifth year, the C3 Prize will award grants and resources totaling $200,000 to concepts that address everyday challenges facing people impacted by cancer. In particular this year, solutions that also ease the increased burden of COVID-19 on cancer care, as well as address health disparities affecting cancer patients, are encouraged.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The C3 Prize is open to all applicants through September 28. Astellas will select the finalists in December 2020. Each finalist will participate in a pitch event in March 2021 to determine the prize winners. Additional applicant information is available at www.C3Prize.com.

"Over the past five years we have sourced hundreds of ideas from people who embody the Astellas Oncology mission to make every day better for those living with cancer," said Mark Reisenauer, senior vice president, oncology business unit, Astellas US. "The COVID-19 pandemic, as well as existing health disparities, adds to the complexity of cancer care, creating additional emotional, financial and physical strain for people impacted by cancer, their loved ones and the medical professionals who care for them. The C3 Prize is uniquely designed to elicit the best ideas to address these challenges."

Cultivating Ideas that Unify Care Around People Living with Cancer
The C3 Prize is not just for complex solutions – ideas can be in the form of support tools, educational efforts, technology solutions and beyond. Past winners include people who have lived with cancer, caregivers, healthcare providers, patient advocates, entrepreneurs and more. Their winning ideas have included a video game designed to keep pediatric patients active and informed, a specialized childcare network that provides stability and normalcy for families, and a first-of-its kind and easy-to-understand digital audio series about cancer.

Celebrity entrepreneur and cancer activist Bill Rancic is lending his support to the 5th Annual C3 Prize for the third consecutive year to generate awareness about the importance of fostering advances in cancer beyond medicine and as host of the pitch event.

"As the husband of a cancer survivor, it’s been an honor to be a part of an effort that puts a spotlight on life-changing cancer care solutions that ease the burden of the cancer journey for patients and their families," Rancic said. "I’ve been inspired and impressed by the creativity of the submissions we have received over the years, and I encourage anyone with an idea or concept to apply."

Tackling Everyday Challenges Facing the Cancer Community
The 5th Annual C3 Prize finalists will participate in a pitch event with an expert panel of volunteer judges: Mark Reisenauer, senior vice president, oncology business unit, Astellas; Margaret Laws, president and CEO, Hopelab; Ebele Mbanugo, executive director, Run for a Cure Africa; Steve Alperin, CEO, SurvivorNet and Steven Collens, CEO, MATTER.

"I’ve dedicated my life to cancer education and awareness, and through my experience with the C3 Prize I have learned that one good idea can make an immeasurable difference," said Ebele Mbanugo, 2018 C3 Grand Prize winner, 2020 C3 Prize judge and founder/executive director of the nonprofit organization Run For a Cure Africa (RFCA). "Through the grants we’ve received from the C3 Prize to help fund my idea, we’ve been able to provide more comprehensive care for breast cancer patients living in Nigeria."

Astellas Oncology will award the Grand Prize winner $100,000 USD in grants, and the two Innovation Prize winners $50,000 USD in grants each. All winners will be provided with access to tools and resources to help them develop and advance their idea, including a yearlong complimentary membership to MATTER, a global healthcare startup incubator, community nexus and corporate innovation accelerator.

All eligible entries will be evaluated on the following criteria: potential impact on people affected by cancer, originality/differentiation from existing solutions, scalability of idea, and the impact of the C3 Prize on the ability to further the idea.

For more information, visit www.C3Prize.com.

About the Astellas Oncology C3 Prize
The Astellas Oncology C3 Prize, launched in 2016, is a global challenge that aims to address the complexities of the cancer journey by funding the best ideas in cancer care beyond medicine. The C3 Prize sparks innovative developments in cancer care, tackling cancer challenges by awarding the winners with prize money and connecting them with resources and support. The C3 Prize directly reflects the mission of Astellas Oncology: striving to make every day better for those impacted by cancer. Astellas maintains no ownership in the ventures funded by the C3 Prize. For more information, visit the website at View Source and follow on social media with the hashtag, #C3Prize.

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results

On August 4, 2020 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) reported financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments (Press release, Deciphera Pharmaceuticals, AUG 4, 2020, View Source [SID1234562798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The second quarter for Deciphera was a transformational one as we launched our first commercial product following the FDA approval of QINLOCK," said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. "We are proud to deliver QINLOCK to advanced GIST patients as the first approved therapy designed specifically for their disease. We are encouraged by the initial results from our first partial quarter of commercial sales, which speaks to both the need for a novel therapy such as QINLOCK in GIST, and our preparedness and determination in ensuring that eligible patients who can benefit from QINLOCK have access to this new treatment option."

Mr. Hoerter continued, "Additionally, we remain focused on advancing our portfolio of innovative medicines to improve the lives of people with cancer and are pleased with the progress of our ongoing pipeline programs, DCC-3014, rebastinib and DCC-3116."

Recent Business Progress

Regulatory and Commercial Updates

QINLOCK(ripretinib)
Received U.S. Food and Drug Administration (FDA) approval for QINLOCK on May 15, 2020 for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Deciphera also announced the approval of QINLOCK by Health Canada and the Australian Therapeutic Goods Administration (TGA). The Company expects to file a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the fourth quarter of this year.
Launched QINLOCK in the U.S. for the treatment of fourth-line GIST and achieved net product revenue of $4.8 million in the first partial quarter of the launch.
Announced, along with Zai Lab Limited, that the China National Medical Products Administration (NMPA) accepted its New Drug Application (NDA) for ripretinib for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Recent Clinical Highlights and Updates Announced Today

QINLOCK(ripretinib)
Two mini oral presentations containing results from the INVICTUS pivotal study and the ongoing Phase 1 study of QINLOCK will be featured during the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2020, being held September 19-21. The titles for the presentations can be found below:
"Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase 1 study"
"Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): update from the phase 3 INVICTUS study"
DCC-3014
Submitted updated data from the Phase 1 dose-escalation study in patients with tenosynovial giant cell tumor (TGCT) to a medical conference taking place in the fourth quarter of this year.
Rebastinib
Data from Part 2 (Stage 1) of the ovarian cancer cohort of the ongoing Phase 1b/2 study in combination with paclitaxel will be featured in an E-poster presentation at the upcoming ESMO (Free ESMO Whitepaper) Virtual Congress 2020 in September.
Data from Part 1 of the Phase 1b/2 study in combination with carboplatin will be featured in an E-poster presentation at the upcoming ESMO (Free ESMO Whitepaper) Virtual Congress 2020 in September.
Second Quarter 2020 Financial Results

Cash Position: As of June 30, 2020, cash, cash equivalents and marketable securities were $631.8 million, compared to $579.6 million as of December 31, 2019. The increase was primarily due to the Company’s follow-on public offering in February 2020 that provided net proceeds of $188.4 million. Based on its current operating plans, Deciphera expects its current cash, cash equivalents and marketable securities together with anticipated product revenues, but excluding any potential future milestone payments or other payments under its collaboration or license agreements, will enable the Company to fund its operating and capital expenditures into the second half of 2022.
Revenue: Total net revenues for the second quarter of 2020 were $7.1 million, which includes $4.8 million of net product revenue of QINLOCK and $2.3 million of collaboration revenue. In the second quarter of 2019, the Company did not generate product revenue and had net collaboration revenues of $25 million.
Cost of Sales: Cost of sales was less than $0.1 million for the second quarter of 2020 as the majority of the manufacturing costs related to second quarter QINLOCK sales were incurred prior to FDA approval, and thus, were recorded as R&D expense. Cost of sales will not be significant until the initial pre-launch inventory is depleted, and additional inventory is manufactured and sold. In the second quarter of 2019, there were no cost of sales as no product sales were generated during that period.
R&D Expenses: Research and development expenses for the second quarter of 2020 were $46.1 million, compared to $34.8 million for the same period in 2019. The increase was primarily due to personnel costs, clinical trial costs related to our Phase 3 INTRIGUE trial in second-line GIST, DCC-3014 and rebastinib, and preclinical costs related to DCC-3116. The increase was partially offset by a decrease in manufacturing costs for QINLOCK primarily due to the commencement of capitalization of inventory as we received FDA approval for QINLOCK in May 2020. Non-cash, stock-based compensation was $5.3 million and $1.8 million for the second quarters of 2020 and 2019, respectively.
SG&A Expenses: Selling, general and administrative expenses for the second quarter of 2020 were $29.9 million, compared to $13.2 million for the same period in 2019. The increase was primarily a result of personnel costs as well as external spend associated with commercial preparedness and launch of QINLOCK, increased expenses incurred in connection with our new headquarters that commenced in October 2019, and technology related costs to support the growth of the business. Non-cash, stock-based compensation was $5.3 million and $2.3 million for the second quarters of 2020 and 2019, respectively.
Net Loss: For the second quarter of 2020, Deciphera reported a net loss of $67.2 million, or $1.20 per share, compared with a net loss of $21.5 million, or $0.56 per share, for the same period in 2019. The increase in net loss was primarily related to increases in R&D and SG&A expenses and the $25.0 million of collaboration revenue recognized in the second quarter of 2019, as discussed above.
Conference Call and Webcast

Deciphera will host a conference call and webcast to discuss this announcement today, August 4, 2020 at 4:30 PM ET. To access the live call by phone please dial (866) 930-5479 (domestic) or (409) 216-0603 (international); the conference ID is 3769662. A live audio webcast of the event may also be accessed through the "Investors" section of Deciphera’s website at www.deciphera.com. A replay of the webcast will be available for 30 days following the event.